摘要
背景:有必要采取更敏感的措施来检测阿尔茨海默病导致的微妙认知衰退。目的:探讨DEM在阿尔茨海默病中的应用。提示-Stroop任务的表现受到临床前阿尔茨海默病神经病理学的影响。 方法:29名认知无症状老年人完成了一项电脑化的线索-Stroop任务,在这项任务中,反应时间的正确率和个体内变异性是INTE的结果。休息一下。测定A、β42和τ的脑脊液生物标志物,然后根据已发表的反映阿尔茨海默病风险的p-τ/Aβ42临界值(临床前Al)将参与者分组。兹海默氏病14例,对照组15例)。 结果:ANOVAS结果表明,各组间的准确率无差异,但4秒钟的延迟、不一致的色命名、Stroop变异系数、反应次数在斜面上均较高,差异有显着性(P<0.05)。L型阿尔茨海默病组与对照组相比,反映了人的变异性增加。此外,部分相关表明脑脊液生物标志物之间没有相关性。和准确率。而变异系数的增加与Aβ42的降低、p-τ和p-τ/Aβ42比值的增加有关。 结论:结果支持计算机,提示-Stroop任务的能力,以检测微妙的阿尔茨海默病神经病理学使用一小群认知无症状的老年人。O测定反应时的线索-Stroop系数在阿尔茨海默病前期具有科学和临床应用价值。
关键词: 阿尔茨海默病、神经心理学、认知神经科学、Stroop试验、生物标志物、个体内变异性、衰老、认知衰退。
Current Alzheimer Research
Title:Differential Cued-Stroop Performance in Cognitively Asymptomatic Older Adults with Biomarker-Identified Risk for Alzheimer’s Disease: A Pilot Study
Volume: 15 Issue: 9
关键词: 阿尔茨海默病、神经心理学、认知神经科学、Stroop试验、生物标志物、个体内变异性、衰老、认知衰退。
摘要: Background: There exists a need for more sensitive measures capable of detecting subtle cognitive decline due to Alzheimer's disease.
Objective: To advance the literature in Alzheimer’s disease by demonstrating that performance on a cued-Stroop task is impacted by preclinical Alzheimer's disease neuropathology.
Method: Twenty-nine cognitively asymptomatic older adults completed a computerized, cued-Stroop task in which accuracy rates and intraindividual variability in reaction times were the outcomes of interest. Cerebrospinal fluid biomarkers of Aβ42 and tau were measured and participants were then grouped according to a published p-tau/Aβ42 cutoff reflecting risk for Alzheimer’s disease (preclinical Alzheimer's disease = 14; control = 15).
Results: ANOVAs indicated that accuracy rates did not differ between the groups but 4-second delay incongruent color-naming Stroop coefficient of variation reaction times were higher in the preclinical Alzheimer’s disease group compared to the control group, reflecting increased within-person variability. Moreover, partial correlations showed no relationships between cerebrospinal fluid biomarkers and accuracy rates. However, increases in coefficient of variation reaction times correlated with decreased Aβ42 and increases in p-tau and the p-tau/Aβ42 ratio.
Conclusion: Results supported the ability of the computerized, cued-Stroop task to detect subtle Alzheimer’s disease neuropathology using a small cohort of cognitively asymptomatic older adults. The ongoing measurement of cued-Stroop coefficient of variation reaction times has both scientific and clinical utility in preclinical Alzheimer’s disease.
Export Options
About this article
Cite this article as:
Differential Cued-Stroop Performance in Cognitively Asymptomatic Older Adults with Biomarker-Identified Risk for Alzheimer’s Disease: A Pilot Study, Current Alzheimer Research 2018; 15 (9) . https://dx.doi.org/10.2174/1567205015666180404170359
DOI https://dx.doi.org/10.2174/1567205015666180404170359 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabotropic Glutamate Receptors in Central Nervous System Diseases
Current Drug Targets New Insights into Biological Markers of Frontotemporal Lobar Degeneration Spectrum
Current Medicinal Chemistry Inhibitors and Breakers of Advanced Glycation Endproducts (AGEs): A Review
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Bioinformatic Analysis of HIV-1 Entry and Pathogenesis
Current HIV Research Atrial Remodeling and Novel Pharmacological Strategies for Antiarrhythmic Therapy in Atrial Fibrillation
Current Medicinal Chemistry The Endocannabinoid System: A Promising Target for the Management of Type 2 Diabetes
Current Protein & Peptide Science Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Cardiovascular & Hematological Disorders-Drug Targets GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future
Current Pharmaceutical Design Aggregation State and Neurotoxic Properties of Alzheimer β-Amyloid Peptide
Current Protein & Peptide Science Cognitive Dysfunction in Depression: Lessons Learned from Animal Models
CNS & Neurological Disorders - Drug Targets Improving Metabolic Control Through Functional Foods
Current Medicinal Chemistry Editorial (An Idea Whose Time Has Come? An African Foresight Observatory on Genomics Medicine and Data-Intensive Global Science)
Current Pharmacogenomics and Personalized Medicine Prevalence of Cognitive Impairment and Dementia in Malays – Epidemiology of Dementia in Singapore Study
Current Alzheimer Research Effect of Simvastatin on Inflammatory Cytokines Balance in Air Pouch Granuloma Model
Inflammation & Allergy - Drug Targets (Discontinued) AtreMorine Treatment Regulates DNA Methylation in Neurodegenerative Disorders: Epigenetic and Pharmacogenetic Studies
Current Pharmacogenomics and Personalized Medicine Neuroprotective Therapy for HIV Dementia
Current HIV Research The Effects of Lipid-Regulating Therapy on Haemostatic Parameters
Current Pharmaceutical Design Stress-Induced Oxidative Changes in Brain
CNS & Neurological Disorders - Drug Targets Subcellular Injuries in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Blood Pressure and Vascular Alterations with Growth in Childhood
Current Pharmaceutical Design